J&J Asks FDA to Expand Caplyta Approval to Bipolar Mania
Johnson & Johnson filed with the FDA to extend Caplyta's approval to manic or mixed episodes in adults with bipolar I disorder, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Johnson & Johnson has sent a request to the US Food and Drug Administration asking it to widen approval of its antipsychotic Caplyta. The application covers manic or mixed episodes linked to bipolar I disorder in adults, according to Dow Jones Newswires, which cited the company. If granted, it would be the drug's fifth authorized use among adults.
Shortly before the filing, the New Brunswick, New Jersey drugmaker said Caplyta had hit its main targets in a second late-stage trial in bipolar mania, Reuters reported.
why it matters
Caplyta is already cleared for depressive episodes tied to bipolar I or II disorder, schizophrenia and major depressive disorder. It was the core asset in J&J's $14.6 billion purchase of Intra-Cellular Therapies last year, so a further label expansion carries weight for the company's neuroscience franchise. The move is company-specific and does not shift the broader market outlook.
market impact
JNJ: a wider label for Caplyta could support future sales of the drug, though the FDA decision is still pending
tags
instruments
sources
- Johnson & Johnson Seeks U.S. FDA Approval For Caplyta In Bipolar Mania, Marking Fifth Potential Indication — Reuters, 19 November 2026 at 13:22 UTC
- Johnson & Johnson Seeks Expanded FDA Approval for Caplyta in Bipolar Mania — Dow Jones Newswires, 19 November 2026 at 13:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗